CEVEC Appoints New Management Team

Cologne, Germany, September 19, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed Chief Business Officer and Frank Ubags joins as Chief Operating Officer.

“Our vision is to become the leading independent player for human cell line based clinical materials. This management team possesses all skills, competencies and experience to achieve this ambitious target."

CAP for Protein Production


CAP and CAP-T Cells exhibit exceptional yields for complex proteins and antibodies. Authentic human-like post-translational modifications allow for higher specific activities and more cost-effective large scale productions of therapeutic molecules. A unique advantage of the transiently protein producing CAP-T Cells and the stably producing CAP Cells are identical and highest product qualities provided by an isogenic cellular background.


CAP for Vaccine Production


CAP Cells exhibit key advantages in the field of vaccine development: adapted to animal component free suspension culture the human amniocyte derived cells propagate a very broad range of clinically relevant human viruses at high titers. Non-tumorous origin, development of the cell line under guidance of ethical advisory committees and a fully documented history from donor to Master Cell Bank position CAP as a versatile mammalian expression host.


Clinical Material


CEVEC is your contract manufacturer of choice for cGMP production in CAP Cells.
CAP-derived clinical material can be provided for phase I-II studies and we produce your desired protein, vaccine, virus or gene therapy vector at extraordinary pace and competitive pricing through our CAP CMO Joint Venture with Genibet in Lisbon/Portugal.